Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners
July 22, 2022 07:35 ET
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Completion of AffinityDNA Acquisition expanding global direct-to-consumer business
July 14, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...
Gene Editing Market Is Expected to Reach $7.4 Billion by 2031, Claims AMR
July 11, 2022 06:37 ET
|
Allied Market Research
Portland, OR, July 11, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global gene editing market was estimated at $3.9 billion in 2021, and is anticipated...
Global Biopharmaceutical and Biomedicine Market to Surpass US$ 1,165,862.8 Million by 2030, Says Coherent Market Insights (CMI)
July 05, 2022 08:40 ET
|
CMI
Seattle, July 05, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global biopharmaceutical and biomedicine market is estimated to be valued at US$ 561,375.9 million in 2022 and...
EasyDNA expands Indian and European markets; launching NIPT, Carrier testing and DNA storage
July 05, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 05, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...
GeneType Risk Assessment Test onboarding in 16 clinics
July 01, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...
Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer Risk Assessment Test
June 16, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...
Acquisition of global direct to consumer ecommerce business
May 16, 2022 09:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...
Genetic Technologies drives leadership in precision medicine with Multi-Risk Test
April 08, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness...
BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair
April 27, 2020 01:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin...